You are here: Industry Insights > Aerie

News List

Aerie Pharmaceuticals Launches GMP Facility contractpharma
October 30, 2018
Aerie Pharmaceuticals Launches GMP Facility
Aerie Announces Drug Application for Approval Accepted for Review in Europe americanpharmaceuticalreview
October 12, 2018
Aerie Pharmaceuticals reported the EMA has accepted for review the MAA for Rhokiinsa (netarsudil ophthalmic solution) 0.02%. Rhokiinsa is currently marketed as Rhopressa in the United States and is indicated for the reduction of elevated intraocular press
Aerie Announces Early Notification of FDA Acceptance of Roclatan americanpharmaceuticalreview
July 24, 2018
Aerie Pharmaceuticals has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) earlier than scheduled, the FDA has completed its initial 60-day review of the NDA
Aerie's glaucoma drug gets strong preliminary FDA opinion pharmafile
October 13, 2017
In a preliminary review of the drug, the FDA has judged that Aerie Pharmaceutical’s experimental glaucoma treatment Rhopressa (netarsudil) effectively reduces intraocular pressure when administered once a day
Aerie raids Alcon again, returning this time with an R&D VP fiercebiotech
September 20, 2017
Aerie Pharmaceuticals has yet again looked to Novartis’ struggling eye care unit for a new hire. Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.